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Background:  In mainland  China,  peginterferon  (PEG-IFN)  alfa-2b  1.0  g/kg/wk  for 24 weeks  is the
approved  treatment  for HBeAg-positive  chronic  hepatitis  B.eceived in revised form 31 July 2014
ccepted 10 August 2014
eywords:
eginterferon
epatitis B
andomized
Objective:  This  multicenter,  randomized  trial evaluated  the  safety  and  efﬁcacy  of regimens  utilizing
increased  dose  or treatment  duration  in  treatment-naive  Chinese  patients  with  chronic  hepatitis  B.
Study  design:  670  HBeAg-positive  patients  from  China,  Malaysia,  Taiwan  area,  Singapore,  and  Thailand
were  enrolled.  Patients  received  PEG-IFN  alfa-2b  1.0  g/kg/wk  (arm  A) or 1.5  g/kg/wk  (arm  B)  for  24
weeks,  or 1.5  g/kg/wk  for 48  weeks  (arm  C).  The  primary  end  point  was  loss  of HBeAg  24  weeks  after
end of  treatment.
Abbreviations: AE, adverse event; AFP, alfa-fetoprotein; ALT, alanine aminotransferase; CI, conﬁdence interval; HbEAb, hepatitis B e antibody; HBeAg, hepatitis B e
ntigen; HbSAb, antibody to hepatitis B surface antigen; HBsAg, surface antigen of the hepatitis B virus; HBV, hepatitis B virus; ITT, intent-to-treat; PEG-IFN, peginterferon;
AE,  serious adverse event.
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510 J. Cheng et al. / Journal of Clinical Virology 61 (2014) 509–516
Results:  At the  end  of  follow-up,  HBeAg  loss  was  signiﬁcantly  greater  in  arm  C compared  with  arm  A (31.3%
vs.  17.3%;  P =  0.001)  and  arm  B  (31.3%  vs. 18.1%;  P =  0.001).  No  signiﬁcant  difference  in the  rate  of  HBeAg
loss  was  observed  between  arms  A and  B.  The  proportions  of  patients  with  HBe  seroconversion,  HBV  DNA
levels  <20,000  IU/mL,  and ALT  normalization  at the  end  of  follow-up  were  signiﬁcantly  higher  in  arm  C
compared  with  arm  A and  arm  B.  In arms  A, B, and C, rates  of  early  treatment  discontinuation  were  6.3%,
4.9%,  and  8.9%;  of  discontinuation  due  to an AE,  2%, 3%, and  3%;  and  of AEs  requiring  dose modiﬁcation,
3%,  6%,  and  10%,  respectively.
Conclusions: In Chinese  patients  with  HBeAg-positive  chronic  hepatitis  B, PEG-IFN  alfa-2b  1.5 g/kg/wk
for 48  weeks  is more  efﬁcacious  compared  with  1.0  and  1.5 g/kg/wk  for  24 weeks.
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. Background
Hepatitis B is a major global health care problem, with estimates
rom the World Health Organization suggesting that approximately
40 million individuals have chronic infection, and an estimated
80,000 die each year as a result of the acute or chronic conse-
uences of HBV infection [1]. These effects are felt most widely
n countries of Asia, such as mainland China, where infection is
ndemic, with an estimated 93 million infected individuals and
00,000 resultant deaths each year [2].
Treatment options for chronic HBV infection include
ucleos(t)ide analogs and interferon-based therapy [3,4]. In
ainland China, the approved dosage of peginterferon (PEG-IFN)
lfa-2b is 1.0 g/kg/wk for 24 weeks; however, studies of this
egimen for durations of up to 52 weeks have generally yielded
elatively modest antiviral effects [5]. Establishing the optimum
ose and treatment duration for PEG-IFN alfa-2b is therefore
mperative to maximize the clinical utility of this treatment.
. Objectives
The aim of the present study was to evaluate the efﬁcacy and
afety of increasing dose and duration of PEG-IFN alfa-2b in patients
ith HBeAg (hepatitis B e antigen)-positive chronic HBV infection
ClinicalTrials.gov identiﬁer: NCT00536263).
. Study design
.1. Patients
Adult patients 18–65 years old with HBeAg-positive chronic
BV infection were enrolled in the study. All patients had con-
rmed detectable serum surface antigen of the HBV (HBsAg) for
 period of ≥6 months, were serum HBsAb (antibody to hepatitis
 surface antigen) and HBeAb (hepatitis B e antibody) nega-
ive, and had plasma HBV DNA levels >20,000 IU/mL. Patients
ad alanine aminotransferase (ALT) levels 2–10 times the upper
imit of normal and were required to have compensated liver
isease with the following minimum hematologic and serum bio-
hemical criteria: neutrophil count ≥1.5 × 109 L−1; platelet count
80 × 109 L−1; prothrombin time prolonged ≤3 s; and total biliru-
in, albumin, and serum creatinine levels within normal ranges.
lfa-fetoprotein (AFP) <100 ng/mL and an ultrasound conﬁrming
he absence of hepatocellular carcinoma for patients with AFP lev-
ls 50–100 ng/mL were also required before enrollment.
Patients who had received prior antiviral treatment for hepatitis
ith any interferon, immunomodulatory, or nucleos(t)ide analog
ithin the previous 6 months were excluded. Patients were also
xcluded if they had a history of immunologic diseases, severe
sychiatric disease, epilepsy, or cardiovascular disease. Patients
ith signiﬁcant hepatic disease from an origin other than HBV, or
ho were coinfected with hepatitis A, C, D, E, or HIV, were also
xcluded.hed  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
3.2. Randomization and masking
This was  a phase 3, multicenter, randomized, open-label study.
Patients were randomly assigned in a 1:1:1 ratio to receive PEG-IFN
alfa-2b 1.0 g/kg/wk (arm A) or 1.5 g/kg/wk (arm B) for a period of
24 weeks, or PEG-IFN alfa-2b (1.5 g/kg/wk) for 48 weeks (arm C).
Randomization was  performed using a centralized procedure based
on a computer-generated code, with patients stratiﬁed according
to HBV genotype. All patients were followed for 24 weeks after
completion of treatment.
3.3. Study end points
This study was  conducted in accordance with principles of Good
Clinical Practice and was  approved by the appropriate institutional
review boards and regulatory agencies. Written informed consent
was obtained for all subjects.
The primary end point for the study was  loss of HBeAg 24 weeks
after end of treatment (end of follow-up). Secondary end points
included the percentage of patients with loss of HBeAg at end of
treatment, as well as HBeAg seroconversion (HBeAg loss and anti-
HBeAg positive) and normalization of ALT at end of treatment and
at end of follow-up. Change in HBV DNA from baseline and the pro-
portions of patients with HBV DNA undetectable, <200 IU/mL, and
<20,000 IU/mL were also evaluated. A combined response (deﬁned
as HBV DNA <20,000 IU/mL, HBe seroconversion, and ALT nor-
malization) at the end of follow-up was  considered a sustained
combined response. HBsAg loss, HBs seroconversion (HBsAg loss
and anti-HBs positive), and mean biopsy score change from base-
line to end of follow-up were also assessed. Safety was evaluated,
and criteria for dose reductions were prespeciﬁed in the proto-
col (to 1.0 g/kg or 0.5 g/kg) for patients unable to tolerate the
prescribed PEG-IFN dose.
3.4. Assay procedures
Assays for HBV DNA (Cobas Taqman with lower limit of
detection of 6 IU/mL; Roche, Nutley, NJ, USA), HBV genotyping
(INNO-LiPA; Innogenetics Inc., Alpharetta, GA, USA), HBeAg, HBeAb,
HBsAg, and HBsAb (all MEIA; Abbott Laboratories, Abbott Park,
IL, USA) were performed at a central laboratory. Other tests were
conducted at local laboratories. Liver biopsies were conducted at
baseline and at ﬁnal follow-up visit in patients enrolled at predes-
ignated mainland China study sites who were willing to undergo
liver biopsy and were sent to a central pathology laboratory for sco-
ring according to the Knodell scoring system. Patients with biopsy
samples before and after treatment were evaluated for improve-or no change (<2 category change) in liver inﬂammation and
ﬁbrosis.
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Fig. 1. Patient ﬂow diagram. AE, adverse event; LTFU, lost to follow-up; PEG-IFN, peginterferon. *One patient did not receive study medication and is accounted for within the
patients who discontinued treatment. †Reasons for not wishing to continue within the study may  be related or unrelated to the assigned treatment. §One patient discontinued
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.5. Statistics
Based on estimated rates of HBeAg loss of 23% in arm A [6],
6% in arm B [7], and 36% in arm C [5], a sample size of 645 sub-
ects (215 subjects per treatment arm) was considered sufﬁcient
o allow the detection of differences between treatment arms (arm
 vs. arm A, or arm C vs. arm A) with 80% power when a 2-sided
.05 signiﬁcance level was used. The intent-to-treat (ITT) popula-
ion included all randomized subjects taking at least 1 dose of study
edication. The per-protocol analysis included those patients who
ulﬁlled all aspects of the protocol and were treated according to the
rotocol.
The superiority primary analysis (arm A vs. arm C) was based
n the ITT population. For primary and secondary end points, the
ochran–Mantel–Haenszel test was used to compare treatment
roups, and Hochberg’s adjustment was applied for multiple com-
arisons. In addition, the noninferiority of arm B vs. arm C was
o be concluded if the lower bound of the 1-sided 95% conﬁ-
ence interval (CI) of the difference in rates of HBeAg loss at end
f follow-up was greater than the noninferiority margin of –10%.
ithin-treatment group comparison was carried out using a paired
 test.
. Results
In total, 670 HBeAg-positive patients were enrolled and received
t least 1 dose of study medication at 26 centers across mainland
hina, Malaysia, Taiwan area, Singapore, and Thailand. More than
5% of participants were enrolled at centers in mainland China.
atient disposition, demographics, and genotype distribution were
roadly similar across treatment arms (Fig. 1 and Table 1). Over-
ll, 9% of patients receiving treatment for 48 weeks discontinued
reatment early compared with 6% and 5% of patients treated for
4 weeks. In total, 7 patients in arm A, 6 patients in arm B, and 2
atients in arm C completed treatment but did not enter follow-
p. One patient in arm A was lost to follow-up and all remaining
4 patients withdrew consent after completing treatment.inuation.
4.1. Efﬁcacy
At the end of follow-up, HBeAg loss was  greater among patients
in arm C than in arm A (31.3% vs. 17.3%; P = 0.001) and arm B (31.3%
vs. 18.1%; P = 0.001; Table 2). In addition, no difference in the rate
of HBeAg loss was noted between arms A and B at the end of
follow-up.
Analysis of secondary efﬁcacy outcomes also showed signiﬁcant
beneﬁt associated with the arm C treatment regimen (Table 3).
At the end of follow-up, the proportions of patients with HBeAg
seroconversion, with HBV DNA levels <20,000 IU/mL, with ALT nor-
malization, and with a combined response was  signiﬁcantly higher
in arm C compared with arm A or B. The decline in HBV DNA
between baseline and the end of follow-up was greater in arm C
compared with arm A (P < 0.001) and arm B (P = 0.001). Rates of
HBsAg loss and HBsAg seroconversion were very low and similar
across treatment arms, and total Knodell biopsy score at the end of
follow-up was  improved compared with baseline in all treatment
arms; however, the degree of improvement did not differ between
groups (Table 3). Results from the per-protocol population closely
paralleled those from the ITT analyses (Table 4).
4.2. Liver histology
No difference in change in liver histology was  noted between
treatment arms (Table 5). At the end of treatment, more than half of
all patients in each arm showed an improvement in hepatic inﬂam-
mation score (Knodell I + II + III), and 63.0–76.6% showed no change
in ﬁbrosis score (Knodell IV).
4.3. Safety
PEG-IFN alfa-2b was well tolerated, with a safety proﬁle that was
similar across all treatment arms (Table 6). Most patients experi-
enced treatment-related adverse events (AEs), the most frequently
reported being pyrexia, myalgia, and headache. In total, 36 patients
reported a serious AE (SAE), of which 21 were considered treatment
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Table 1
Patient characteristics.
PEG-IFN alfa-2b (1.0 g/kg/wk) for
24 weeks
n = 225
PEG-IFN alfa-2b (1.5 g/kg/wk) for
24 weeks
n = 221
PEG-IFN alfa-2b (1.5 g/kg/wk) for
48 weeks
n = 224
Male, % 76 74 75
Age,  y, mean (SD) 28.2 (7.2) 27.5 (7.1) 28.4 (7.6)
Weight,  kg, mean (SD) 63.5 (11.4) 63.2 (11.6) 63.40 (11.6)
BMI,  kg/m2, mean (SD) 22.3 (2.9) 22.1 (3.2) 22.2 (3.2)
Baseline HBV DNA, log10 IU/mL, mean (SD) 7.8 (0.9) 7.8 (0.8) 7.8 (0.8)
HBV  genotype, %
B 44 46 46
C  54 52 53
Other 2 2 1
Total  Knodell HAI score, mean (SD) 8.2 (3.3) 8.3 (2.8) 8.6 (3.2)
Baseline alanine aminotransferase, IU/mL,
mean (SD)
173 (93.7) 186 (106) 170 (81.4)
B IFN, p
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CMI, body mass index; HAI, histological activity index; HBV, hepatitis B virus; PEG-
elated by study investigators (Table 6). In arm A, exacerbation of
epatitis (n = 3) was the only event reported as an SAE in more than
 patient, and in arm B, fatigue, decreased appetite (n = 3 each),
nd hepatitis B exacerbation and depression (n = 2 each) were the
ost frequently reported SAEs. In arm C, 48 weeks of therapy was
ot associated with an increased incidence of SAEs: exacerbation
f hepatitis B and elevated ALT were reported in 2 patients. Fur-
hermore, discontinuation of therapy due to an AE was  similar
cross treatment groups, occurring in 3% of patients in arms B and
 compared with 2% in arm A. No individual AE caused treatment
iscontinuation in more than 1 patient. Overall, AEs requiring dose
odiﬁcation occurred in 6% of all patients and at a slightly higher
ate in arm C compared with arm A (10% vs. 3%).
Hematologic toxicity was generally rated as mild to moderate
y study investigators. The proportions of patients requiring dose
odiﬁcation as a result of neutropenia (<1.0 × 109 L−1) were similar
cross treatment arms (11% in arm A, 16% in arm B, and 18% in arm
), and 3 patients were discontinued from treatment because of
eutropenia. Similarly, 8 patients (4 patients from arm C and 2 each
rom arms A and B) required treatment discontinuation because
heir platelet count was <50 × 109 L−1.
. DiscussionPrior to the conduct of this study, PEG-IFN alfa-2b 1.0 g/kg/wk
or 24 weeks was one of the standard treatment regimens
or patients with HBeAg-positive chronic HBV infection in
able 2
rimary outcome by treatment group (intent-to-treat analysis).
Arm A Arm B Arm C 
PEG-IFN alfa-2b
(1.0 g/kg/wk) for
24 weeks
n = 225
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
24 weeks
n = 221
PEG-IFN alfa-2b
(1.5 g/kg/wk) f
48 weeks
n = 224
HBeAg loss, n (%)
EOT (end of treatment) 31 (13.8) 28 (12.7) 43 (19.2) 
24  weeks after EOT 39 (17.3) 40 (18.1) 70 (31.3) 
I, conﬁdence interval; PEG-IFN, peginterferon.eginterferon; SD, standard deviation.
mainland China [6]. Several recent studies suggest that prolong-
ing the treatment duration and increasing the dosage of PEG-IFN is
associated with improved response rates in patients with chronic
HBV infection. In the NEPTUNE study, HBeAg seroconversion rates
were higher in patients receiving PEG-IFN alfa-2a (180 g/wk)
for 48 weeks compared with those receiving the same dose for
24 weeks (36.2% vs. 25.8%). Using a 2 × 2 factorial design, this
study showed that both higher dose (180 g/wk vs. 90 g/wk) and
extended treatment duration (48 weeks vs. 24 weeks) were signif-
icantly associated with improved treatment outcomes [7].
Results of the present study indicate that extending the dura-
tion of treatment with PEG-IFN alfa-2b to 48 weeks and increasing
the dose to 1.5 g/kg/wk is associated with a signiﬁcant improve-
ment in efﬁcacy. Almost one-third of patients receiving PEG-IFN
(1.5 g/kg/wk) for 48 weeks achieved HBeAg loss 24 weeks after
completion of treatment compared with 17% of those receiving
the currently approved regimen of 1.0 g/kg/wk for 24 weeks. In
addition, most secondary end points revealed improved efﬁcacy
associated with the longer treatment duration. Patients in arms
A and B were followed for 24 weeks after completion of ther-
apy; therefore, week 72 data are not available for patients in these
arms for comparison with end of follow-up data in arm C. Finally,
no difference between treatment arms regarding change in liver
histology was noted: most patients showed improvement in
hepatic inﬂammation score with no change in ﬁbrosis score.
Safety observations from the present study are also consistent
with the known safety proﬁle of PEG-IFN alfa-2b in patients with
Pairwise comparison
(95% CI)
P  value
or
B vs. A C vs. A B vs. C
−0.011
(−0.074 to 0.052)
P  = 0.700
0.054
(−0.014 to 0.123)
P  = 0.125
−0.065
(−0.122 to −0.008)
P  = 0.061
0.008
(−0.063 to 0.079)
P  = 0.860
0.139
(0.061 to 0.217)
P = 0.001
−0.132
(−0.198 to −0.065)
P  = 0.001
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Table  3
Secondary outcomes by treatment group (intent-to-treat analysis).
Arm A Arm B Arm C Pairwise comparison
(95% CI)
P value
PEG-IFN alfa-2b
(1.0 g/kg/wk) for
24 weeks
n = 225
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
24 weeks
n = 221
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
48 weeks
n = 224
B vs. A C vs. A B vs. C
HBeAg seroconversion, n (%)
EOT (end of treatment) 31 (13.8) 27 (12.2) 40 (17.9) −0.016
(−0.078 to 0.047)
P = 0.598
0.041
(−0.027 to 0.108)
P = 0.240
−0.056
(−0.112 to −0.001)
P  = 0.098
24  weeks after EOT 38 (16.9) 36 (16.3) 67 (29.9) −0.006
(−0.075 to 0.063)
P = 0.830
0.130
(0.053–0.208)
P = 0.001
−0.136
(−0.201 to −0.071)
P  = 0.001
HBV  DNA levels at EOT, n (%)
<20,000 IU/mL 46 (20.4) 61 (27.6) 76 (33.9) 0.072
(−0.007 to 0.151)
P = 0.076
0.135
(0.053–0.216)
P = 0.001
−0.063
(−0.135 to 0.009)
P = 0.145
<200  IU/mL 10 (4.4) 14 (6.3) 21 (9.4) 0.019
(−0.023 to 0.061)
P = 0.373
0.049
(0.003–0.096)
P = 0.040
−0.030
(−0.072 to 0.011)
P  = 0.235
Undetectable 4 (1.8) 3 (1.4) 8 (3.6) –0.004
(−0.027 to 0.019)
P = 0.724
0.018
(−0.012 to 0.048)
P = 0.243
−0.022
(−0.046 to 0.002)
P  = 0.132
HBV  DNA levels at 24 weeks after EOT, n (%)
<20,000 IU/mL 44 (19.6) 47 (21.3) 75 (33.5) 0.017
(−0.058 to 0.092)
P = 0.662
0.139
(0.059–0.220)
P = 0.001
−0.122
(−0.191 to −0.053)
P  = 0.003
<200  IU/mL 12 (5.3) 12 (5.4) 22 (9.8) 0.001
(−0.041 to 0.043)
P = 0.969
0.045
(−0.004 to 0.094)
P  = 0.074
−0.044
(−0.085 to −0.003)
P  = 0.081
Undetectable 4 (1.8) 3 (1.4) 8 (3.6) –0.004
(−0.027 to 0.019)
P = 0.724
0.018
(−0.012 to 0.048)
P = 0.232
−0.022
(−0.046 to 0.002)
P  = 0.134
ALT  normalization, n (%)
EOT 75 (33.3) 86 (38.9) 103 (46.0) 0.056
(−0.033 to 0.145)
P = 0.219
0.126
(0.037–0.216)
P = 0.006
−0.071
(−0.148 to 0.006)
P = 0.131
24  weeks after EOT 63 (28.0) 80 (36.2) 103 (46.0) 0.082
(−0.004 to 0.168)
P = 0.067
0.180
(0.092–0.268)
P < 0.001
−0.098
(−0.174 to −0.021)
P  = 0.032
Combined response, n (%)
EOT 11 (4.9) 11 (5.0) 23 (10.3) 0.001
(−0.039 to 0.041)
P = 0.995
0.054
(0.005–0.103)
P = 0.031
−0.053
(−0.094 to −0.012)
P  = 0.036
24  weeks after EOT 18 (8.0) 23 (10.4) 45 (20.1) 0.024
(−0.030 to 0.078)
P = 0.389
0.121
(0.058–0.184)
P < 0.001
−0.097
(−0.152 to −0.041)
P  = 0.004
HBsAg  loss, n (%)
EOT 1 (0.4) 1 (0.5) 4 (1.8) 0.000
(−0.012 to 0.012)
P = 0.991
0.013
(−0.006 to 0.033)
P  = 0.181
−0.013
(−0.030 to 0.003)
P = 0.175
24  weeks after EOT 1 (0.4) 1 (0.5) 4 (1.8) 0.000
(−0.012 to 0.012)
P = 0.971
0.013
(−0.006 to 0.033)
P  = 0.179
−0.013
(−0.030 to 0.003)
P = 0.182
HBsAg  seroconversion, n (%)
EOT 0 0 1 (0.4) 0.000
(N/A)
P > 0.999
0.004
(−0.004 to 0.013)
P  = 0.322
−0.004
(−0.012 to 0.003)
P  = 0.317
24  weeks after EOT 0 0 2 (0.9) 0.000
(N/A)
P > 0.999
0.009
(−0.003 to 0.021)
P  = 0.157
−0.009
(−0.019 to 0.001)
P  = 0.160
Total  Knodell biopsy score change from baseline, mean (SE)a
24 weeks after EOT −1.6 (0.74) −1.8 (0.77) −1.8 (0.76) −0.2 (−1.2 to 0.8)
P  = 0.631
−0.3 (−1.4 to 0.8)
P  = 0.617
0.0 (−1.1 to 1.1)
P  = 0.953
Log10 HBV DNA (IU/mL) change from baseline, mean (SE)
EOTb −1.6 (0.26) −1.9 (0.26) −2.1 (0.26) −0.3 (−0.7 to 0.1)
P  = 0.094
−0.6 (−1.0 to −0.2)
P = 0.005
0.2 (−0.2 to 0.6)
P  = 0.248
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Table 3 (Continued)
Arm A Arm B Arm C Pairwise comparison
(95% CI)
P value
PEG-IFN alfa-2b
(1.0 g/kg/wk) for
24 weeks
n = 225
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
24 weeks
n = 221
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
48 weeks
n = 224
B vs. A C vs. A B vs. C
24 weeks after EOTc −1.1 (0.32) −1.2 (0.32) −2.0 (0.32) −0.1 (−0.5 to 0.4)
P = 0.807
−0.9 (−1.3 to −0.4)
P < 0.001
0.8 (0.4–1.3)
P = 0.001
ALT  change from baseline (×ULN), mean (SE)
EOTd −2.2 (0.24) −2.2 (0.25) −2.3 (0.25) 0.0 (0.4–0.3)
P = 0.868
−0.2 (0.5–0.2)
P = 0.351
0.1 (0.2–0.5)
P = 0.451
24  weeks after EOTe −0.8 (0.42) −0.9 (0.41) −1.4 (0.41) 0.0 (−0.7 to 0.6)
P = 0.898
−0.6 (−1.2 to 0.0)
P = 0.052
0.6 (−0.1 to 1.2)
P  = 0.073
ALT, alanine aminotransferase; CI, conﬁdence interval; EOT, end of treatment; HBV, hepatitis B virus; PEG-IFN, peginterferon; SE, standard error; ULN, upper limit of normal.
a Least squares mean. n = 64, n = 64, and n = 46 for arms A, B, and C, respectively; P value from an ANCOVA model with treatment group and genotype as the ﬁxed effects
and  baseline as covariate.
b Least squares mean. n = 212, n = 205, and n = 204 for arms A, B, and C, respectively; P value from an ANCOVA model with treatment group and genotype as the ﬁxed effects
and  baseline as covariate.
c Least squares mean. n = 193, n = 178, and n = 189 for arms A, B, and C, respectively; P value from an ANCOVA model with treatment group and genotype as the ﬁxed effects
and  baseline as covariate.
d Least squares mean. n = 214, n = 202, and n = 207 for arms A, B, and C, respectively; P value from an ANCOVA model with treatment group and genotype as the ﬁxed effects
and  baseline as covariate.
e Least squares mean. n = 199, n = 191, and n = 194 for arms A, B, and C, respectively; P value from an ANCOVA model with treatment group and genotype as the ﬁxed effects
and  baseline as covariate.
Table 4
Selected analyses for the per-protocol population.
Arm A Arm B Arm C Pairwise comparison
(95% CI)
P value
PEG-IFN alfa-2b
(1.0 g/kg/wk) for
24 weeks
n = 206
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
24 weeks
n = 198
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
48 weeks
n = 211
B vs. A C vs. A B vs. C
HBeAg seroconversion, n (%)
EOT 30 (14.6) 24 (12.1) 40 (19.0) −0.024
(−0.091 to 0.042)
P  = 0.469
0.044
(−0.028 to 0.115)
P  = 0.230
−0.068
(−0.127 to −0.010)
P  = 0.059
24  weeks after EOT 35 (17.0) 31 (15.7) 64 (30.3) −0.013
(−0.085 to 0.059)
P  = 0.718
0.133
(0.053–0.214)
P = 0.001
−0.147
(−0.214 to −0.080)
P  < 0.001
Combined response, n (%)
EOT 11 (5.3) 11 (5.6) 23 (10.9) 0.002
(−0.042 to 0.046)
P  = 0.917
0.056
(0.004–0.108)
P = 0.039
−0.053
(−0.098 to −0.009)
P  = 0.049
24  weeks after EOT 18 (8.7) 22 (11.1) 44 (20.9) 0.024
(−0.035 to 0.082)
P  = 0.429
0.121
(0.054–0.188)
P < 0.001
−0.097
(−0.156 to −0.039)
P  = 0.008
CI, conﬁdence interval; EOT, end of treatment; PEG-IFN, peginterferon.
Table 5
Effects of treatment on liver inﬂammation and ﬁbrosis.
PEG-IFN alfa-2b
(1.0 g/kg/wk)
for 24 weeks
PEG-IFN alfa-2b
(1.5 g/kg/wk)
for 24 weeks
PEG-IFN alfa-2b
(1.5 g/kg/wk)
for 48 weeks
Change in hepatic inﬂammation scores (Knodell I + II + III), n (%) n = 65 n = 65 n = 47
Improved 37 (56.9) 35 (53.8) 28 (59.6)
No  change 11 (16.9) 15 (23.1) 6 (12.8)
Worse  17 (26.2) 15 (23.1) 13 (27.6)
Change  in hepatic ﬁbrosis score (Knodell IV), n (%) n = 64 n = 66 n = 46
Improved 5 (7.8) 12 (18.2) 10 (21.7)
No  change 49 (76.6) 45 (68.2) 29 (63.0)
Worse  10 (15.6) 9 (13.6) 7 (15.2)
PEG-IFN, peginterferon. Liver biopsy was performed at screening and at week 48 follow-up only at designated sites in mainland China.
Improvement (≥2 category decrease), worsening (≥2 category increase), no change (<2 category change).
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Table  6
Adverse events.
PEG-IFN alfa-2b
(1.0 g/kg/wk) for
24 weeks
n = 225
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
24 weeks
n = 221
PEG-IFN alfa-2b
(1.5 g/kg/wk) for
48 weeks
n = 224
Treatment-related any adverse event (AEs), n (%) 181 (80) 182 (82) 194 (87)
Treatment-related AEs (≥5% incidence), n (%)
Pyrexia 156 (69) 158 (71) 168 (75)
Myalgia 54 (24) 70 (32) 77(34)
Headache 47 (21) 66 (30) 59(26)
Fatigue 35(16) 32 (14) 42 (19)
Dizziness 18 (8) 21 (10) 22 (10)
Arthralgia 18 (8) 13 (6) 12 (5)
Alopecia 15 (7) 18 (8) 27 (12)
Asthenia 12 (5) 25 (11) 15 (7)
Decreased appetite 8(4) 19(9) 17(8)
Chills 9(4) 10 (5) 10 (4)
Decreased weight 5 (2) 3 (1) 14 (6)
Nausea 5 (2) 11 (5) 9 (4)
Treatment-related serious AEs, n (%) 8 (4) 7 (3) 6 (3)
Deaths, n (%) 0 0 0
Discontinuation due to AEs, n (%) 5 (2) 6 (3) 7 (3)
Dose  reduction or interruption due to AEs, n (%) 6 (3) 13 (6) 22 (10)
Hematology, n (%)
Neutrophil count <1.0 × 109 L−1 41 (18) 52 (24) 62 (28)
Dose  reductiona due to neutropenia (<1.0 × 109 L−1) 40 (18) 52 (24) 60 (27)
Discontinuation due to neutropenia (<0.5 × 109 L−1) 1 (<1) 0 2 (1)
Platelet count <70 × 109 L−1 26(12) 19 (9) 21(10)
Dose  reductiona due to thrombocytopenia (<70 × 109 L−1) 24(10) 17 (8) 17 (8)
9 −1
 
P
 by 0.5
H
4
r
r
g
w
w
5
t
A
a
a
m
t
t
w
t
S
a
p
m
t
o
(
p
w
a
p
h
S
e
(
mDiscontinuation due to thrombocytopenia (<50 × 10 L ) 2(1)
EG-IFN, peginterferon.
a Protocol-mandated PEG-IFN alfa-2b dose reduction: starting dose was  reduced
BV infection [8]. Extending the treatment duration from 24 to
8 weeks was  not associated with an increase in total treatment-
elated AEs or SAEs, although an increase in AEs requiring dose
eduction or interruption was observed in the 48-week treatment
roup. The frequency of AEs leading to treatment discontinuation
as similar in the 24- and 48-week treatment arms.
The HBV 99-01 study compared PEG-IFN alfa-2b (100 g/wk)
ith PEG-IFN alfa-2b plus lamivudine (100 mg/day) each for
2 weeks in 266 patients with HBeAg-positive chronic HBV infec-
ion [5,8]. In this study, van Zonneveld et al. [8] noted that most
Es experienced by patients receiving PEG-IFN alfa-2b monother-
py occurred before week 32 of therapy, with neutropenia reported
s the single most frequent AE leading to discontinuation or dose
odiﬁcation. In the present study, extending treatment dura-
ion beyond 24 weeks did not result in a substantial increase in
reatment-limiting toxicity, suggesting that most AEs associated
ith PEG-IFN alfa-2b are likely to occur early during the course of
herapy.
The present study enrolled patients from Malaysia, Taiwan area,
ingapore, and Thailand, although most (657 of 670) were recruited
t centers in mainland China. Data from this study therefore sup-
ort the use of PEG-IFN alfa-2b 1.5 g/kg/wk for 48 weeks in
ainland Chinese patients with HBeAg-positive chronic HBV infec-
ion. This conclusion is supported by a subgroup analysis including
nly those patients enrolled at study centers in mainland China
shown in Supplementary Tables 1 and 2). In this analysis, the pro-
ortion of Chinese patients with HBeAg loss at the end of follow-up
as higher in arm C than in arm A (30.9% vs. 17.7%; P = 0.001) and
rm B (31.3% vs. 18.5%; P = 0.002). In addition, the proportion of
atients with a combined response at the end of follow-up was
igher in arm C than in arm A (P = 0.001) and arm B (P = 0.008;
upplementary Table 2). The relatively small number of patients
nrolled across Malaysia, Taiwan area, Singapore, and Thailand
n = 13) limits the generalizability of these data to patients outside
ainland China.2(1) 4 (2)
 g/kg/wk.
Recent studies have indicated that HBsAg quantization, HBeAg,
and other indices may  be used to predict response to PEG-IFN
in patients with chronic HBV infection [9–12]. Unfortunately, the
present study was conducted at a time when quantitative assays
for HBsAg and HBeAg were unavailable. However, samples col-
lected during the present study have been retained, providing the
opportunity for further studies on HBsAg/HBeAg quantization to be
conducted in the future.
In conclusion, these data indicate that reduction in HBeAg
24 weeks after treatment cessation is signiﬁcantly greater among
patients receiving PEG-IFN alfa-2b 1.5 g/kg/wk for 48 weeks com-
pared with those receiving a dose of 1.0 g/kg/wk or 1.5 g/kg/wk
for 24 weeks. Increased efﬁcacy in patients treated with the
1.5 g/kg/wk dose for 48 weeks did not appear to be accompanied
by a clinically meaningful increase in drug-related AEs.
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